Recurrence in resected gastroenteropancreatic neuroendocrine tumors
Menée à partir de données canadiennes portant sur 936 patients atteints d'une tumeur neuroendocrine gastro-entéro-pancréatique (âge médian au diagnostic : 60 ans ; durée médiane de suivi : 46,8 mois), cette étude analyse les taux de récidive à 5 et 10 ans après une première résection de la tumeur
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are widely heterogeneous malignant abnormalities.1 Their natural history is poorly described, with little understanding of recurrence patterns. Surveillance for resected GEP-NETs may include clinical review, laboratory tests, and numerous medical and nuclear imaging modalities. These modalities can increase patient anxiety, may be associated with potential harm (eg, exposure to ionizing radiation), and have not been shown to improve outcomes. Current guidelines vary widely in recommendations, reflecting the lack of data.2,3 Information on the natural history and recurrence of the disease may improve patient-centered follow-up of this population. We hypothesized that GEP-NETs may recur over a longer time course compared with other gastrointestinal malignant abnormalities.
JAMA Oncology 2018